ELK1 and mantle cell lymphoma: A study about Carfilzomib sensitivity in mantle cell lymphoma, a hematological malignancy for which proteasome inhibitors are an approved therapy, investigated the role of Elk1 in proteasome capacity and inhibitor resistance [109].